GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifeward Ltd (NAS:LFWD) » Definitions » Sloan Ratio %

LFWD (Lifeward) Sloan Ratio % : 0.00% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Lifeward Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Lifeward's Sloan Ratio for the quarter that ended in Dec. 2024 was 0.00%.

As of Dec. 2024, Lifeward has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Lifeward Sloan Ratio % Historical Data

The historical data trend for Lifeward's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifeward Sloan Ratio % Chart

Lifeward Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.12 -1.29 -2.23 26.40 -

Lifeward Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lifeward's Sloan Ratio %

For the Medical Devices subindustry, Lifeward's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifeward's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lifeward's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Lifeward's Sloan Ratio % falls into.


;
;

Lifeward Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Lifeward's Sloan Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2024 )-Cash Flow from Operations (A: Dec. 2024 )
-Cash Flow from Investing (A: Dec. 2024 ))/Total Assets (A: Dec. 2024 )
=(-28.942--21.718
-0)/30.487
=-23.70%

Lifeward's Sloan Ratio for the quarter that ended in Dec. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2024 )
=(-28.942--21.718
-0)/30.487
=-23.70%

Lifeward's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was -6.276 (Mar. 2024 ) + -4.304 (Jun. 2024 ) + -3.084 (Sep. 2024 ) + -15.278 (Dec. 2024 ) = $-28.94 Mil.
Lifeward's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was -7.673 (Mar. 2024 ) + -5.617 (Jun. 2024 ) + -4.459 (Sep. 2024 ) + -3.969 (Dec. 2024 ) = $-21.72 Mil.
Lifeward's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) + 0 (Dec. 2024 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifeward  (NAS:LFWD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2024, Lifeward has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Lifeward Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Lifeward's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifeward Business Description

Traded in Other Exchanges
N/A
Address
200 Donald Lynch Boulevard, Marlborough, MA, USA, 01752
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
Executives
Turk Joseph E Jr director NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
Randel Richner director C/O REWALK ROBOTICS, LTD., 3 HATNUFA ST. 6TH FL. P.O. BOX 161, YOKNEAM L3 2069203
Lawrence J Jasinski director, officer: Chief Executive Officer SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
Jeannine Lynch officer: VP of Market Access & Strategy C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., P.O. BOX 161, YOKNEAM ILIT L3 20692203
Michael A Lawless officer: Chief Financial Officer C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Lind Global Fund Ii Lp 10 percent owner 444 MADISON AVENUE, 41ST FLOOR, NEW YORK NY 10022
Lind Global Macro Fund Lp 10 percent owner 444 MADISON AVE, FLOOR 41, NEW YORK NY 10022
Jeff Dykan director KOCHAV YOKNEAM BUILDING, FLOOR 6, P.O. BOX 161, YOKNEAM ILIT L3 20692
Aryeh Dan director KOCHAV YOKNEAM BUILDING, FLOOR 6, P.O. BOX 161, YOKNEAM ILIT L3 20692
Charles Remsberg officer: Chief Sales Officer C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Poduska John William Sr director 295 MEADOWBROOK RD, WESTON MA 02493
Yasushi Ichiki director KOCHAV YOKNEAM BUILDING, FLOOR 6, P.O. BOX 161, YOKNEAM ILIT L3 20692
Yohanan Engelhardt director 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Hadar Levy director C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355